In conclusion, these cases as well as burgeoning ongoing research demonstrates that, combining BV with active, intensive chemotherapy regimens can be used in primary refractory CD30+ NHL with improved efficacy compared with traditional treatment and with acceptable and manageable toxicities. The gene discussed is TNFRSF8; the disease is non-Hodgkin lymphoma.